J&J Restarts ENSEMBLE Vaccine Study in the USA

New Jersey-based Johnson & Johnson announced on October 23, 2020, that it is preparing to resume recruitment in the pivotal Phase 3 ENSEMBLE trial of its investigational Janssen COVID-19 vaccine Ad5-nCoV in the USA after a temporary pause. 'After a thorough evaluation of a serious medical event experienced by one study participant, no clear cause has been identified,' said the company's press statement.